Cure8 trial brief
This trial explores whether delivering sodium propionate directly to the colon can alter the gut microbiome and immune markers in people with Crohn’s disease and whether it offers similar or added benefits compared with butyrate — a better‑studied short‑chain fatty acid.
Adults with Crohn’s disease in remission or mild activity; gastroenterologists and IBD researchers interested in microbiome and SCFA‑based interventions.
The study enrolls about 50 adults with Crohn’s disease and uses a 45‑day treatment period per arm (three capsules daily), a washout, then crossover so each person receives both propionate and butyrate.
Primary outcomes center on shotgun metagenomic analysis of stool to measure microbiota composition and metabolic pathways; blood cytokines and patient‑reported IBDQ scores are secondary/exploratory measures.
The propionate formulation is microencapsulated to target colonic release and is being studied because propionate is a short‑chain fatty acid with potential immunomodulatory and microbiota‑modifying effects that are less well studied than butyrate.
Registry entry describes a small, randomized, double‑blind crossover pilot study focused on microbiome sequencing and biomarker changes. It is not a large efficacy trial, and the registry does not contain results.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
People with stricturing Crohn’s disease currently lack effective medical treatments to prevent or reverse intestinal fibrosis; this trial explores a probiotic approach (and trehalose) aimed at stimulating autophagy, a...
This trial tests a safe, non-drug supplement (GlcNAc) as a precision-medicine approach for Crohn's disease based on a genetic variant that affects glycosylation. If successful, it could offer a new, well-tolerated...
The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...
